Serafin Morales - Dissemin

Papers authored by Serafin Morales

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

2017 Serafin Morales

Efficacy and safety of biosimilar ABP 980 compared with trastuzumab in HER2 positive early breast cancer

Upload

Serafin Morales

Vitamin D as a prognostic factor in triple negative early breast cancer

Upload

Serafin Morales

SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (with or without letrozole in ER plus ) in previously trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer

Upload

2016 A. Novell, Serafin Morales

, J. Valls, Panadés Mj, M. J. Panadés, A. Salud

, E. Iglesias, F. Vilardell, X. Matias Guiu, A. Llombart Cussac

Novel biomarkers in primary breast core biopsies to predict poor response to neoadjuvant chemotherapy and appearance of metastases.

Upload

This paper was not found in any repository, but could be made available legally by the author.

Jdela de la Haba, E. Aranda Aguilar, S. Morales

, J. A. García-Sáenz, A. Guerrero, N. Martínez, A. Antón, M. Muñoz, M. Ramos, M. Gil-Gil, M. Margelí, S. Servitja, B. Bermejo, J. Cruz, A. Rodríguez Lescure and 5 other authors

ACE and CXCL10 as predictive biomarkers in the LEA study

Upload

Ian E. Krop, Ingrid A. Mayer, Vinod Ganju, Maura Dickler, Stephen Johnston, Serafin Morales

, Denise A. Yardley, Bohuslav Melichar, Andres Forero-Torres, Soo Chin Lee, Richard de Boer, Katarina Petrakova, Susanne Vallentin, Edith A. Perez, Martine Piccart and 9 other authors

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial

Upload

Luca Gianni, Mauro Mansutti, Antonio Anton, Lourdes Calvo, Giancarlo Bisagni, Begoña Bermejo, Vladimir Semiglazov, Marc Thill, Jose Ignacio Chacon, Arlene Chan, Serafin Morales

, Isabel Alvarez, Arrate Plazaola, Milvia Zambetti, Andrew D. Redfern and 5 other authors

ETNA (Evaluating Treatment with Neoadjuvant Abraxane) randomized phase III study comparing neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer: A MICHELANGO study.

Upload

Antonio Llombart-Cussac, Manuel Ramos, Elsa Dalmau, José A. García-Saenz

, Xavier González-Farré

, Laura Murillo

, Lourdes Calvo

, Serafín Morales

, Vicente Carañana, Ana González, Luis A. Fernández-Morales, Fernando Moreno, Mª Isabel Casas, Mª del Mar Angulo, Mª Carmen Cámara and 3 other authors

Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study

Upload

A. Prat, V. Ortega, L. Paré, P. Galván, M. Oliveira, P. Nucíforo, A. Lluch, S. Morales

, K. Amillano, R. Lopez, R. González, L. Manso, J. Martínez, A. Llombart, L. de la Peña and 5 other authors

Abstract P3-07-66: Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study

Upload

A. Prat, J. de la Haba-Rodriguez, Á. Guerrero, Ja García-Sáenz, S. Morales

, A. Antón, M. Muñoz, M. Ramos, N. Martínez-Jáñez, M. Margelí, S. Servitja, F. Rojo, P. Galván, S. González, J. Cruz and 7 other authors

Abstract P3-07-42: Predicting outcome and benefit to first-line bevacizumab in advanced/metastatic hormone receptor (HR)+/HER2-negative breast cancer (BC) treated with endocrine therapy: A correlative science study from the LEA phase III clinical trial (GEICAM/2006-11_GBG 051)

Upload

R. Wuerstlein, A. Prat, Ortega, L. Pare, P. Galvan, P. Nuciforo, M. Oliverira, K. Amillano, R. Lopez, A. Lluch, S. Morales

, R. Gonzales, L. Manso, J. Martinez, A. Llombart and 6 other authors

Efficacy and gene expression results from SOLTI1007, a phase II study evaluating neoadjuvant eribulin in hormone receptor (HR)-positive/HER2-negative breast cancer

Upload

This paper is made freely available by the publisher.

F. Mateo, E. J. Arenas, H. Aguilar, J. Serra-Musach, G. Ruiz de Garibay, G. R. De Garibay, J. Boni, M. Maicas, S. Du, F. Iorio, C. Herranz-Ors

, A. Islam, X. Prado, A. Llorente, A. Petit and 81 other authors

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

Download from www.nature.com

2015 J. Gavilá, S. Lopez Tarruella, C. Saura, M. Muñoz, M. Oliveira, L. De la Cruz Merino, S. Morales

, I. Alvarez, J. A. Virizuela, M. Martin

SEOM clinical guidelines in metastatic breast cancer 2015

Download from link.springer.com

This paper is available in a repository.

Antonio Llombart-Cussac, Begoña Bermejo, Cristian Villanueva, Suzette Delaloge, Serafín Morales

, Judith Balmaña, Kepa Amillano, Hervé Bonnefoi, Ana Casas, Luis Manso, Henri Roché, Santiago Gonzalez-Santiago, Joaquín Gavilá, Pedro Sánchez-Rovira, Serena Di Cosimo and 6 other authors

SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer

Download from www.researchgate.net

Sambasivarao Damaraju, Vera Gorbunova, Karen A. Gelmon, Jose Angel Garcia Saenz, Serafin Morales

, Dany Youssef Abigerges, Jean-Luc Canon, Igor Lifirenko, Graham Lawrence Cohen, Guy Heinrich Maria Jerusalem, Francois Thireau, Rodrigo Fresco, Vincent Houé, Michael F. Press, Ashok Narasimhan and 1 other authors

Relationship of germline polymorphisms to docetaxel toxicity in the ROSE/TRIO-012 trial.

Upload

Serafin Morales

, Ariadna Gasol Cudós, Antonieta Salud, Noemí Tuset Der-Abrain, Juan Felipe Cordoba Ortega, Antonia Salud

Clinical and histopathological risk associated with brain metastasis-free survival in breast cancer.

Upload

Miguel J. Gil-Gil, M. Bellet, S. Morales

, B. Ojeda, L. Manso, C. Mesia, E. Garcia-Martínez, N. Martinez-Jáñez, M. Melé

, A. Llombart, S. Pernas, P. Villagrasa, C. Blasco, J. Baselga

Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study

Upload

Helena Verdaguer, Serafin Morales

, Valentí Navarro, Alba Martinez Lopez, Anna Petit, Fina Climent, Oriol Casanovas, Sònia Pernas

Abstract P6-01-05: Potential biomarkers of response to primary antiangiogenic and hormonal therapy in post-menopausal women with hormone-positive, HER2-negative primary breast cancer:

Upload

Hope S. Rugo, Olivier Tredan, Jungsil Ro, Serafin Morales

, Antonino Musolino, Noemia Afonso, Marta Ferreira, Kyong Hwa Park, Javier Cortes, Antoinette R. Tan, Joanne L. Blum, Lamar Eaton, Christine K. Gause, Adelle (Zhen) Wang, Ellie Im and 2 other authors

Abstract PD5-1: Results from the phase 2 trial of ridaforolimus, dalotuzumab, and exemestane compared to ridaforolimus and exemestane in advanced breast cancer

Upload

Miguel Martín, Milagros González-Rivera, Serafín Morales

, Juan de la Haba, Lucía González-Cortijo, Luis Manso, Joan Albanell, Antonio González-Martín, Sónia González, Angels Arcusa, Luis de la Cruz-Merino, Federico Rojo, Maria Vidal, Uxue Goicoechea, Patricia Galván and 5 other authors

Abstract P6-08-10: Prospective study of the impact of the Prosigna™ assay on adjuvant clinical decision-making in women with estrogen receptor-positive, HER2-negative, node-negative breast cancer: A GEICAM study:

Upload

Missing publications? Search for publications with a matching author name.

Researcher

Statistics

Refine

Papers authored by Serafin Morales